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Background: Risk factors for initial Pseudomonas aeruginosa (Pa) acquisition, particularly environmental exposures, are poorly understood. We
aimed to identify such risk factors in order to inform prevention strategies and identify high-risk populations.
Methods: The study cohort included all participants in the U.S. EPIC Observational Study who had no prior Pa-positive respiratory cultures
(N=889). Cox proportional hazard models were used to test the effects of factors on age at ﬁrst Pa-positive respiratory culture.
Results: Cystic ﬁbrosis (CF) genotype functional class had an important effect on age at initial Pa acquisition (hazard ratio (HR) comparing
minimal to residual CFTR function 2.87 (95% CI 1.88, 4.39)). None of the modiﬁable risk factors evaluated, including cigarette smoke, hot tub
use, breastfeeding, or daycare, was associated with age at Pa acquisition. Similarly, newborn screening was not associated with age at Pa
acquisition (HR 0.85, 95% CI 0.66, 1.09). Key associations were validated in a CF Foundation National Patient Registry replication cohort.
Conclusions: Given the ubiquitous presence of Pa in the environment, it may be that many imposed lifestyle changes will have less impact on age
at initial Pa acquisition than genetic determinants.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pseudomonas; Risk factors; Epidemiology; Exposure; Environment1. Introduction
The primary cause of morbidity and mortality in patients with
cystic fibrosis (CF) is progressive obstructive pulmonary disease
and bronchiectasis due to chronic endobronchial infection.
Pseudomonas aeruginosa (Pa), a ubiquitous environmental
bacterium, is a key pathogen in CF lung disease. Pa infection☆ These results were presented in abstract form at the North American Cystic
Fibrosis Conference, New Orleans, Louisiana, USA, May, 2009 [1].
⁎ Corresponding author at: 4800 Sandpoint Way NE, Mail Stop A-5937, PO
Box 5371, Seattle, WA 98105-0371, USA. Tel.: +1 206 987 5644; fax: +1 206
987 2639.
E-mail address: margaret.rosenfeld@seattlechildrens.org (M. Rosenfeld).
1 Participating clinical sites and investigators are listed in the online supplement,
Appendix 1.
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doi:10.1016/j.jcf.2012.04.003can begin very early in life, and the prevalence of Pa in
respiratory cultures increases with age [2]. Chronic Pa infection is
clearly associated with worse outcomes, including survival, lung
function, chest radiograph scores, pulmonary exacerbations and
nutritional status [3–5]. In general, CF patients progress from
initial, often transient, Pa infection amenable to eradication to
chronic infection with mucoid Pa that is virtually impossible to
eradicate [6,7]. Current guidelines of care emphasize identifica-
tion and eradication of initial Pa infection in an effort to delay or
prevent chronic infection [8–12].
Our current understanding of risk factors for initial Pa
acquisition is limited. While CF patients are frequently
counseled to avoid hot tubs or swimming pools, there has
been no evaluation of home environmental exposures as risk
factors for initial Pa acquisition. Three small studies evaluatedby Elsevier B.V. All rights reserved.
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concordant and some conflicting results [13–15]. The only
characteristic consistently associated with age at Pa acquisition
has been cystic fibrosis transmembrane conductance regulator
(CFTR) genotype [14,16–19]. Despite early concerns that
newborn screening might be associated with earlier acquisition
of Pa [15], more recent studies have not implicated it as a risk
factor [20–22].
The EPIC Observational Study (EPIC OBS) [23,24] is a U.S.
national prospective study specifically designed to better define
risk factors for age at first isolation of Pa from respiratory
cultures, particularly modifiable exposures such as daycare
attendance, breastfeeding or environmental tobacco smoke.
Such risk factors have not to our knowledge been previously
evaluated. Identification of these risk factors could inform
prevention strategies and identify high-risk populations requiring
closer monitoring. We also evaluated the generalizability of key
findings in a separate sample from the U.S. Cystic Fibrosis
Foundation National Patient Registry (CFNPR).
2. Methods
2.1. EPIC OBS study participants
The design of the EPIC OBS Study has been reported
[23,24]. Children with an established diagnosis of CF [25]
≤12 years of age were enrolled at 59 accredited U.S. CF care
centers between 2004 and 2006. The current analysis cohort is
composed of all EPIC OBS participants who had no isolation of
Pa from respiratory cultures both prior to and within 120 days
after enrollment (as such individuals likely actually acquired Pa
prior to enrollment). Written informed consent was obtained
from the family of each participant and the study was approved
by the Institutional Review Board at each participating site.
2.2. EPIC OBS data
Study data were collected at each clinical encounter via the
CFNPR and study-specific forms, as previously reported [23].
Respiratory cultures were obtained and processed at local site
labs as per clinical protocol, and results reported in the CFNPR.
A questionnaire was administered to families at enrollment and
annually, assessing exposure to a wide range of potential risk
factors for Pa acquisition (see Appendix 2, online supplement
(OLS)). The data cut-off date for the current analysis was
December 31, 2009.
2.3. CFNPR replication cohort
In order to assess the generalizability of our results, a
replication cohort was assembled from the U.S. CFNPR.
Eligibility criteria mimicked those of the EPIC OBS cohort.
See OLS for details. Data for the replication cohort was limited
to that available in the CFNPR and thus does not include data
from the annual family survey such as exposures or socioeco-
nomic status or encounter-based data regarding therapies.2.4. Analysis
The primary endpoint for this analysis was age at initial Pa
acquisition, defined as the age at first isolation of Pa from a
clinically-collected respiratory culture (oropharyngeal, sputum
or bronchoalveolar lavage). Categorization of CFTR function
was based on CFTR mutation functional class [19,24,26,27]:
“minimal,” both alleles with mutations in class 1, 2 or 3;
“residual,” at least one allele with a mutation class 4 or 5. See
OLS for further details of CFTR functional classification.
Cox proportional hazards regression models were used to
compute hazard ratios (HR) and 95% confidence intervals
(CIs), testing the effect of fixed and time-varying covariates on
age at Pa acquisition. Participants entered the analysis at their
age at study entry. Participants who did not acquire Pa were
censored at the age of their latest recorded respiratory culture.
For time-varying covariates, Cox model estimates were derived
using information about the participants at risk at each failure
time.3. Results
3.1. Participant characteristics at enrollment
A total of 1032 EPIC OBS Study participants had no
isolation of Pa from a respiratory culture prior to enrollment,
among which 143 were excluded due to Pa acquisition or loss
to follow up during the first 120 days after enrollment. Thus,
889 participants comprise the EPIC OBS cohort for the current
analysis. In the CFNPR, there were 10,577 CF patients born
between 1992 and 2006, not enrolled in the EPIC OBS Study
and alive in 2004. A total of 3,649 of these subjects had at
least one encounter between November 2004 and October
2006, of which one encounter was chosen at random as the
entry date, and had no Pa-positive cultures prior to that
date. Nine hundred thirty seven were excluded due to Pa
acquisition or loss to follow up during the first 120 days
after study entry. Thus, 2712 subjects comprise the CFNPR
replication cohort.
Demographic and clinical characteristics of the EPIC OBS
cohort are shown in Table 1. As participants were enrolled prior
to widespread CF newborn screening in the U.S., only 20%
were identified by screening. Approximately 80% of partici-
pants received pancreatic enzyme replacement therapy and
almost half used dornase alfa at enrollment. The mean (SD)
length of follow up was 3.9 (0.7) years.
The characteristics of the CFNPR replication cohort were
generally similar (Table 1), except that a greater proportion
could not be assigned a CFTR functional class and a lower
percentage reported dornase alfa use, likely reflecting differen-
tial data collection methods in the two studies. In the EPIC
OBS study, data on dornase alfa use was recorded in study-
specific encounter forms as well as through the CFNPR
encounter forms. The reported rate of dornase alfa use among
EPIC OBS participants based only on CFNPR data was 13.7%,
comparable to that reported in the CFNPR replication cohort.
Table 1
Characteristics at enrollment.
EPIC OBS
cohort
(N=889)
CFNPR
replication
cohort
(N=2712)
Demographics N % N %
Gender Female 446 50.2 1281 47.2
Race Caucasian 856 96.3 2510 92.6
Ethnicity Not Hispanic 816 91.8 2443 90.1
Hispanic 36 4.0 269 9.9
CFTR mutations ΔF508 homozygous 398 44.8 1163 42.9
ΔF508 heterozygous 348 39.1 977 36.0
Other 105 11.8 426 15.7
CFTR functional class a Minimal 633 71.2 1697 62.6
Residual 113 12.7 262 9.7
Unclassified 105 11.8 607 22.4
Meconium ileus 176 19.8 514 19.0
Diagnosis by screening b 192 21.6 473 17.4
Mean SD Mean SD
Age at diagnosis (years) 1.2 2.2 1.4 2.4
Age at enrollment/entry (years) 4.6 3.5 5.0 3.9
Cultures per year while on study 4.2 1.3 3.5 1.5
Weight percentile 40.5 28.9 37.3 29.1
Height percentile 36.6 27.4 34.6 27.5
BMI percentile c 54.5 27.2 51.1 28.4
FEV1 percent predicted
d 98.8 17.5 94.8 17.8
Treatments
Pancreatic enzymes 704 79.2 2059 75.9
DNase 407 45.8 505 18.6
High dose ibuprofen 2 0.2 9 0.3
Inhaled hypertonic saline 6 0.7 76 2.8
Inhaled antibiotics 37 4.2 128 4.7
Organisms isolated from respiratory cultures e
S. aureus 443 52.2 1140 42.0
Methicillin resistant S. aureus 48 5.7 199 7.3
H. influenzae 220 25.9 503 18.5
S. maltophilia 40 4.7 115 4.2
A. xylosoxidans 5 0.6 25 0.9
B. cepacia 1 0.1 14 0.5
Within each characteristic, column totals may not add up to 100% due to
missing data.
a Minimal, both alleles with mutations resulting in minimal CFTR function
(class 1, 2, or 3), includes ΔF508; Residual, at least one allele with a mutation
resulting in partial CFTR function (class 4 or 5); Unclassiﬁed, both alleles with
unknown functional class, or 1 allele with minimal CFTR function and the
second with unknown functional class.
b Diagnosis by prenatal or newborn screening.
c BMI, body mass index. Children age 2 years or older.
d Children age 6 years or older. Percent predicted based on reference
equations of Wang et al. [40] as per CF Foundation recommendations since all
participants b12 years at enrollment.
e Among children with culture results within 120 days following enrollment
or entry date; not mutually exclusive.
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Fig. 1. Kaplan–Meier survival curves for age at initial acquisition of
Pseudomonas aeruginosa. a: EPIC observational cohort vs CFNPR replication
cohort. b: Among EPIC Observational study participants, by CFTR functional
class.
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Of the 889 EPIC OBS participants, 412 (46%) acquired Pa
during 2611 person-years. Thus the rate of Pa acquisition was
16 cases (95% CI 14, 17) per 100 person-years. Among those
acquiring Pa, the median age at acquisition was 3.25 years(95% CI 2.77, 4.03). In comparison, among all U.S. CF patients
in the CFNPR born during the same years as the EPIC OBS
participants (N=10,921), the median age at initial acquisition
for the registry cohort was 4.00 years (95% CI 3.88, 4.16).
Fig. 1a displays the Kaplan–Meier survival curve for time to
initial Pa acquisition. The source of the initial Pa isolate was an
oropharyngeal culture in 335 (81%), sputum in 66 (16%),
bronchoalveolar lavage in 9 (2%), and unknown in 2 (0.5%).
The initial isolate was non-mucoid in 297 (72%), mucoid in 42
(10%), and of unknown status in 73 (18%).
The Pa acquisition rate was similar in the CFNPR replication
cohort: 16 cases (95% CI 15, 17) per 100 person-years. Median
age at acquisition among those acquiring Pa was also similar:
3.63 (95% CI 3.16, 4.05) years, as was time to acquisition
(Fig. 1a, p=0.73). The source of the initial Pa isolate was an
oropharyngeal culture in 69%, sputum in 29% and bronchoscopy
in 2%. Seventy percent were non-mucoid, 13% mucoid and 17%
were of unknown status, similar to the EPIC OBS cohort.
3.3. Risk factors for age at initial Pa acquisition
The effects of demographic characteristics on age at Pa
acquisition are shown in Table 2. In the EPIC OBS cohort,
Table 2
Univariate Cox models for demographic characteristics a.
EPIC OBS cohort CFNPR replication cohort
Risk factor N in model Hazard ratio 95% CI P value N in model Hazard ratio 95% CI P value
Female 889 1.08 0.89, 1.30 0.44 2712 1.12 1.00, 1.26 0.05
Non-white race 887 0.99 0.64, 1.54 0.96 2696 0.83 0.65, 1.06 0.14
Hispanic ethnicity 852 0.95 0.57, 1.58 0.83 2712 1.19 0.99, 1.43 0.06
CFTR function: minimal 851 2.87 1.90, 4.35 b0.0001 2566 2.65 2.02, 3.47 b0.0001
CFTR function: unclassified 1.80 1.08, 2.99 0.02 2566 1.61 1.19, 2.16 0.002
Genotype: both alleles ΔF508 851 1.39 0.98, 1.99 0.07 2566 1.86 1.53, 2.26 b0.0001
Genotype: one allele ΔF508 1.06 0.74, 1.53 0.75 2566 1.35 1.10, 1.65 0.004
Diagnosis age (years) 889 1.00 0.95, 1.05 0.96 2697 0.97 0.94, 0.99 0.02
Meconium ileus 853 1.09 0.87, 1.37 0.46 2685 1.20 1.04, 1.37 0.01
Diagnosis by screening b 738 0.85 0.66, 1.08 0.18 2271 0.74 0.62, 0.87 0.0003
a Separate Cox models were developed for each characteristic. The reference groups are: male sex, white race, non-Hispanic ethnicity, residual CFTR function,
neither allele deltaF508, no history of meconium ileus, and not diagnosed by prenatal or newborn screening. The number of children contributing observations to each
model varied due to missing data.
b Diagnosis by prenatal or newborn screening: the reference group excludes children with a family history of CF.
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acquisition compared to residual CFTR function: HR 2.87
(95% CI 1.90, 4.35, pb0.0001). Kaplan–Meier survival curves
for CFTR functional groups are displayed in Fig. 1b; median
age at Pa acquisition was 2.9 years among participants with
minimal CFTR function vs. 10.3 years for those with residual
CFTR function. No other significant effects of demographic
characteristics on age at Pa acquisition were detected.
Diagnosis by screening was not associated with earlier Pa
acquisition (HR 0.85, 95% CI 0.66, 1.08, p=0.18).
In the CFNPR replication cohort, the effects of demographic
characteristics on age at initial Pa acquisition were similar in
magnitude and direction of to those observed in the EPIC OBS
cohort (Table 2). Due to the larger size of the replication cohort,
more associations were statistically significant. Female gender
was associated with a significantly increased risk of Pa
acquisition (HR 1.12, 95% CI 1.00, 1.26, p=0.05). Minimal
CFTR function and homozygous delta F508 genotype were
associated with significantly increased risk of Pa acquisition, as
was a history of meconium ileus. Later age at diagnosis (HR
0.97, 95% CI 0.94, 0.99 for each integer year of age, p=0.02)
and identification by newborn screening (HR 0.74, 95% CI
0.62, 0.87, p=0.0003) were protective. After adjustment for the
potential confounding effects of gender, race, ethnicity and
CFTR functional class, diagnosis age and meconium ileus were
no longer significant predictors of age at Pa acquisition (data
not shown). Diagnosis after newborn screening remained
protective (adjusted HR 0.81, 95% CI 0.68, 0.96, p=0.02).
Table 3 displays the results of Cox models for the effect of
clinical characteristics at enrollment on age at Pa acquisition,
adjusted for CFTR functional class, race, ethnicity and
identification by newborn screening. In the EPIC OBS cohort,
use of pancreatic enzymes was associated with earlier age at Pa
acquisition even after adjustment for CFTR functional class
(HR 1.78, 95% CI 1.03, 3.09). There were no significant
associations of Dornase alfa, use of any inhaled therapy, weight
percentile, BMI percentile, percent predicted FEV1 or respira-
tory culture results with age at Pa acquisition. Similarly,
persistent infection (a time-varying covariate defined as theproportion of cultures since enrollment positive for the
organism of interest) was not associated with age at Pa
acquisition (data not shown).
In the CFNPR cohort, the directions of the effects of
baseline clinical characteristics on age at Pa acquisition were
similar, but additional significant associations were observed
(Table 3). Use of pancreatic enzymes was associated with
earlier age at Pa acquisition (HR 2.53, 95% CI 1.78, 3.58,
pN0.0001). Greater weight percentile (HR 0.995, 95% CI
0.993, 0.998, p=0.0001), height percentile (HR 0.996, 95% CI
0.994, 0.999, p=0.007) and percent predicted FEV1 (HR 0.992,
95%CI 0.985, 0.998) were protective. Isolation of Staphylococcus
aureus, Stenotrophomonas maltophilia and Achromobacter
xylosoxidans from the baseline respiratory culture were associated
with significantly earlier age at Pa acquisition.
The prevalence of reported exposures from the questionnaire
completed by families at enrollment into the EPIC OBS Study
is described in Table 4. About 75% received the influenza
vaccine in the previous season, and about 30% reported
exposure to cigarette smoke in the household. About one third
of children b6 were in daycare N9 hours per week and about a
third of children b2.5 years received palivizumab passive
immunization in the prior respiratory syncytial virus (RSV)
season.
The associations of exposures reported by parents annually
on the family questionnaire (as time-varying risk factors) and
age at Pa acquisition are shown in Table 5. Influenza vaccine in
the past year appeared borderline protective (HR 0.77, 95% CI
0.59, 1.00, p=0.05). Adjustment for CFTR functional class did
not affect these results (data not shown). Swimming pool use in
the past year also appeared protective (HR 0.69, 95% CI 0.52,
0.90, p=0.007), possibly due to confounding by an unmea-
sured characteristic such as overall lung health and level of
physical activity. No association was detected between
exposure in the past year to cigarette smoke, wood burning
stoves, hot tubs, attendance at social events with others with
CF, daycare/preschool, breastfeeding, palivizumab or socio-
economic status (household income and maternal education),
and age at Pa acquisition.
Table 3
Multivariate Cox models for baseline clinical characteristics a.
Risk factor EPIC OBS cohort CFNPR replication cohort
N in model Hazard ratio 95% CI P value N in model Hazard ratio 95% CI P value
Pancreatic enzymes 627 1.78 1.03, 3.09 0.04 1910 2.52 1.78, 3.57 b0.0001
DNase 677 1.03 0.83, 1.28 0.81 2152 1.07 0.91, 1.26 0.41
Any inhaled medication b 677 0.96 0.77, 1.19 0.71 – – – –
Weight percentile 630 0.998 0.994, 1.00 0.38 2057 0.995 0.993, 0.998 0.0001
Height percentile 624 0.998 0.994, 1.00 0.39 1992 0.996 0.994, 0.999 0.007
BMI percentile c 435 0.997 0.992, 1.00 0.35 1395 0.997 0.994, 1.00 0.08
FEV1 percent predicted
d 194 0.998 0.988, 1.01 0.63 688 0.992 0.985, 0.998 0.01
S. aureus 654 1.05 0.84, 1.30 0.68 1798 1.23 1.07, 1.42 0.004
MRSA 654 0.88 0.53, 1.44 0.61 1798 1.08 0.85, 1.38 0.52
H. influenzae 654 0.96 0.76, 1.21 0.72 1798 1.14 0.96, 1.34 0.13
S. maltophilia 654 1.08 0.71, 1.66 0.71 1798 1.37 1.04, 1.81 0.03
A. xylosoxidans 654 1.11 0.48, 2.56 0.80 1798 1.91 1.08, 3.38 0.03
a Each row in the table shows results for a separate Cox model. The number of children contributing observations to each model varied due to missing data. Each
model was adjusted for CFTR risk group, race, ethnicity, gender, and diagnosis by screening.
b Not evaluated in the replication cohort as data on inhaled bronchodilators or inhaled corticosteroids not available.
c Children age 2 years or older at enrollment.
d Children age 6 years or older at enrollment.
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represent an unusual population by virtue of having survived
without acquiring Pa up to the age at enrollment, we repeated
our evaluation of risk factors among the participants who were
enrolled below the median age of Pa acquisition in the
replication cohort (3.6 years) and found very similar results
(OLS Figure E1, Tables E1, E2 and E3).Table 4
Exposures reported on family surveys at enrollment in EPIC observational
cohort.
Exposure in past year N % a
Total number of participants with enrollment survey completed 866 –
Influenza vaccine 669 77.2
Household member smoked cigarettes 253 29.2
Mother smoked during pregnancy 120 13.9
Wood-burning stove used in home 82 9.5
Hot-tub use 194 22.4
Swimming pool use 613 70.8
Social event with others with CF 129 14.9
Daycare or preschool b 214 37.7
Breastfed c 138 52.3
Received palivuzimab d 104 34.0
Mother's education
High school graduate or less 237 27.4
Some college or more 602 69.5
Annual household income
b$20,000 79 9.1
$20,000–39,000 145 16.7
$40,000–59,000 132 15.2
$60,000–79,000 124 14.3
$80,000–99,000 93 10.7
≥$100,000 152 17.5
Don't know or missing 141 16.3
a Denominator is 866, except as noted. For exposures other than annual
household income, the number of surveys with missing data ranged from 6 to
50.
b Children younger than 6 years (N=567).
c Children younger than 2 years (N=264).
d Children younger than 2.5 years (N=306).4. Discussion
The EPIC Observational Study sheds light on risk factors for
initial Pa acquisition. Ours is the first study to evaluate home
environmental exposures as potential risk factors. None of the
modifiable risk factors that we evaluated, including breastfeed-
ing, daycare attendance, hot tubs or wood burning stoves, was
associated with age at initial Pa acquisition. Given that families
are frequently counseled to make lifestyle changes to minimize
early Pa exposure, these results have important implications
for counseling CF families. Instead, genetic factors had anTable 5
Univariate Cox models for time-varying risk factors reported on annual family
surveys in EPIC observational cohort.
Risk factor a N in
model
Hazard
ratio
95% CI P value
Influenza vaccine during past year 864 0.77 0.59, 1.00 0.05
Household member smokes cigarettes 866 0.96 0.78, 1.18 0.70
Wood-burning stove used in home 864 0.78 0.55, 1.12 0.18
Hot-tub use during past year 866 0.82 0.65, 1.05 0.12
Swimming pool use during past year 866 0.69 0.52, 0.90 0.007
Social event with others with CF
during past year
864 1.09 0.83, 1.42 0.54
Daycare or preschool during past year b 551 0.90 0.70, 1.17 0.45
Breastfed during past year c 261 0.85 0.60, 1.21 0.38
Received palivuzimab during past year d 284 1.02 0.75, 1.40 0.89
Maternal education beyond high school e 839 0.90 0.74, 1.11 0.33
Annual household income: ≥$80,000 e 725 1.05 0.81, 1.35 0.73
Annual household income:
$40,000–$79,000 e
1.03 0.80, 1.33 0.81
a From separate Cox model for each risk factor, modeled as a time-varying
covariate. The number of children contributing observations to each model
varied due to missing data.
b Children younger than 6 years.
c Children younger than 2 years.
d Children younger than 2.5 years.
e As reported at enrollment; the reference group for annual income is
b$40,000.
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minimal function (both mutations in functional class 1, 2 or
3) were associated with earlier Pa acquisition compared to
mutations with residual function (at least one mutation in
functional class 4 or 5); the median age at Pa acquisition was
2.9 years among participants with minimal CFTR function vs.
10.3 years for those with residual CFTR function. A recent
study by Collaco et al. found that ambient temperature is
associated with age at Pa acquisition; in two retrospective
cohorts, age at Pa acquisition was 9 to 15 months earlier in the
warmest temperature quartile compared to the coldest [28].
This effect appears relatively small compared to that of CFTR
functional class. Given the ubiquitous presence of Pa in the
environment, it may be that many imposed lifestyle changes
will have less impact on age at initial Pa acquisition than
genetic determinants.
Age at initial Pa acquisition is likely to be affected by a
complex interplay between host and environmental factors. The
consistent finding by us and others [14,16,17,19] that CFTR
functional status is associated with age at Pa acquisition is an
example of the role of host factors in Pa acquisition. Loss of
CFTR function may predispose to endobronchial infection
either by altering properties of airway surface liquid, thus
impairing innate defenses and bacterial clearance [29], or
because CFTR may bind directly to Pa [30]. Indeed, in the
neonatal CF pig, the lack of CFTR function appears to globally
impair bacterial eradication [31].
Concerns regarding earlier acquisition of Pa among infants
identified by newborn screening have existed since the
Wisconsin Neonatal Screening Trial, in which the benefits of
newborn screening were offset by earlier acquisition of Pa at one
site in the early years of the study [15]. Since that time, several
studies have found no evidence of earlier Pa acquisition among
newborn-screened infants [20–22]. Similarly, we found no
evidence of earlier acquisition of Pa among EPIC OBS
participants diagnosed by newborn screening. In fact, in the
CFNPR replication cohort newborn screening was associated
with a significant delay in age at Pa acquisition. However, it
should be noted that newborn screening in the U.S. was limited to
several states at the time of CF diagnosis in our two cohorts. It is
not possible to separate the independent effects of newborn
screening from those of the environment or monitoring and
treatment practices in those states performing newborn screening.
The baseline characteristics and rates of Pa acquisition were
very similar between the EPIC OBS and the CFNPR replication
cohorts. In addition, the median age at acquisition of Pa among
the EPIC OBS participants was very similar to that seen in all
U.S. CF patients born during the same years in the CFNPR:
3.25 vs. 4.00 years. The effects of demographic and clinical
risk factors on age at initial Pa acquisition were also in general
similar between the EPIC OBS and CFNPR replication cohorts,
though there were some discrepancies in the magnitude of the
effects and in statistical significance, mostly due to the larger
size of the replication cohort. Female gender and a history
of meconium ileus were associated with earlier age at Pa
acquisition in the CFNPR replication cohort, similar to findings
in prior studies [13,14,32], though meconium ileus was nolonger a significant risk factor after adjustment for CFTR
functional class. In the EPIC OBS cohorts, while the hazard
ratios were similar to those in the replication cohort, the
associations were not statistically significant. Thus, the effect of
gender on age at Pa acquisition remains unclear, and the effect
of meconium ileus appears to be mediated through CFTR
functional class. Interestingly, greater weight and height
percentiles at enrollment were significantly protective in the
replication cohort, as was reported recently by Ranganathan et
al. [33]. The possible association of better nutritional status
with delayed acquisition of Pa deserves further exploration, and
may reflect underlying disease severity or a true protective
effect of better nutrition.
Finally, isolation of S. aureus, S. maltophilia and A.
xylosoxidans were each associated with significantly earlier
age at Pa acquisition in the replication cohort. In prior studies,
S. aureus was found to be a risk factor for early age at initial Pa
acquisition in a newborn-screened cohort [15], while it was
found to be protective against mucoid Pa infection in an older
CF cohort [32]. Thus, the role of S. aureus in Pa infection
remains unclear. The observed association of S. maltophilia and
A. xylosoxidans with earlier Pa acquisition may reflect
acquisition of these organisms with more intensive antibiotic
treatment and thus more severe lung disease, or perhaps more
effective ascertainment of these organisms at the same sites that
most effectively culture Pa from respiratory cultures.
We found a borderline protective effect of the influenza
vaccine on age at Pa acquisition. Infections with viruses such as
influenza may trigger pulmonary exacerbations and contribute
to structural airway damage [34], thereby increasing suscepti-
bility to Pa. While aerosol medications were a risk factor for Pa
acquisition in a prior small study [15], we found no association
between use of any inhaled medications and age at Pa
acquisition.
Assuming 412 Pa acquisition events, 80% power and
alpha=0.05, we had an adequate sample size to detect a hazard
ratio of 1.47 for a risk factor with 15% prevalence (such as
participating in a social event with others with CF) and a hazard
ratio of 1.35 for a risk factor with 30% prevalence (such as
cigarette smoke exposure or breastfeeding). We would have
missed associations with lower hazard ratios, though such
associations might not be overly significant from a clinical or
public health standpoint. In addition, we may have missed a
true association due to our measurement methods (parent report
rather than direct measurement) and limited frequency of
assessment (annually). We were unable to assess the effect of
these exposures in the replication cohort as the CFNPR does
not contain data on these exposures. In addition, there were
certainly potential risk factors that we did note evaluate, such as
viral respiratory infections or cohorting practices. These
potential risk factors deserve further investigation.
In our study, we used oropharyngeal (OP) cultures as the
primary endpoint. In the U.S. OP swabs are the standard
method for collecting respiratory cultures in non-expectorating
CF patients. While they have reasonable specificity, OP
cultures have limited sensitivity compared to simultaneous
lower airway cultures [35]. Thus, our conclusions regarding
452 M. Rosenfeld et al. / Journal of Cystic Fibrosis 11 (2012) 446–453risk factors may be more relevant for upper than lower airway
Pa acquisition. In addition, our eligibility criteria, including
enrolling children up to 12 years of age, were designed to be
concordant with the EPIC Clinical Trial [36], a randomized,
controlled trial of early Pa eradication regimens nested in the
EPIC Observational Study. To address concerns that the older
participants in the EPIC OBS cohort might represent an unusual
population since by definition they had not acquired Pa by the age
at enrollment, we repeated our analyses among the participants
who were enrolled before 3.6 years, the median age of Pa
acquisition in the replication cohort, and found similar results.
What are the implications of our results for CF clinics? We
did not evaluate the effects of cohorting practices on risk of Pa
acquisition, as this has previously been evaluated [37,38]. There
is no evidence that the risk of patient-to-patient transmission is
less among those with residual CFTR function, so we would not
recommend that patients with residual CFTR function be
managed differently from an infection control standpoint or
that clinics should be segregated by CFTR function.
How should our results be interpreted when counseling
families? Continuing to recommend the annual influenza vaccine
is warranted. Our results do not reduce the controversy over the
role of palivizumab in infants with CF. The negative effects of
cigarette smoke exposure on lung function have been clearly
documented [39], and socializing with others with CF is known
to increase the risk of acquiring transmissible epidemic Pa strains
[40] so these exposures should be avoided. Given that we were
unable to detect evidence of earlier Pa acquisition among those
exposed to swimming pools, hot tubs or wood burning stoves,
limited contact with these exposures may be reasonable. Relaxing
restrictions on these exposures may reduce anxiety and improve
quality of life for some CF patients and their families.
Acknowledgements
The authors wish to thank all the site investigators and
research coordinators, listed below, as well as all the participants
in the EPIC Observational Study and their families.
Sources of support
Cystic Fibrosis Foundation grants OBSERV04K0 and
EPIC0K0 to M. Rosenfeld, Seattle Children's Hospital, Seattle,
WA, Nemours Children's Clinic Research Program, Jacksonville,
FL. The study sponsors had no role in the study design; the
collection, analysis and interpretation of data; the writing of the
manuscript; or in the decision to submit the manuscript for
publication.
Clinical trials registration
NCT00676169.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.04.003.References
[1] Rosenfeld M, Emerson J, Joubran K, Morgan W, Gibson R, for the EPIC
Study Group. Risk factors for early pseudomonas acquisition in a large
cohort of young US CF patients. Pediatr Pulmonol 2009;S32:373.
[2] Cystic Fibrosis Foundation. National Patient Registry 2010 Annual Data
Report; 2011. Bethesda, Maryland.
[3] Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al.
Acceleration of lung disease in children with cystic fibrosis after
Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32(4):277–87.
[4] Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL.
Pseudomonas aeruginosa and other predictors of mortality and morbidity
in young children with cystic fibrosis. Pediatr Pulmonol 2002;34(2):
91–100.
[5] Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al.
Risk factors for rate of decline in forced expiratory volume in one second
in children and adolescents with cystic fibrosis. J Pediatr 2007;151(2):
134–9 [9 e1].
[6] Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al.
Longitudinal development of mucoid Pseudomonas aeruginosa infection
and lung disease progression in children with cystic fibrosis. JAMA
2005;293(5):581–8.
[7] Pressler T, Frederiksen B, Skov M, Garred P, Koch C, Hoiby N. Early rise
of anti-pseudomonas antibodies and a mucoid phenotype of Pseudomonas
aeruginosa are risk factors for development of chronic lung infection—a
case control study. J Cyst Fibros 2006;5(1):9–15.
[8] Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A,
et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic
fibrosis: a European consensus. Eur Respir J 2000;16(4):749–67.
[9] Doring G, Hoiby N. Early intervention and prevention of lung disease in
cystic fibrosis: a European consensus. J Cyst Fibros 2004;3(2):67–91.
[10] Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas
aeruginosa infection. J Cyst Fibros 2005;4(Suppl. 2):49–54.
[11] Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for
intermittent Pseudomonas aeruginosa airway colonization in cystic
fibrosis patients: 15 years experience. J Cyst Fibros 2008;7(6):523–30.
[12] Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear
SL, et al. Cystic Fibrosis Foundation evidence-based guidelines for
management of infants with cystic fibrosis. J Pediatr 2009;155(6 Suppl.):
S73–93.
[13] Kerem E, Corey M, Stein R, Gold R, Levison H. Risk factors for
Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr
Infect Dis J 1990;9(7):494–8.
[14] Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso
FJ. Risk factors for initial acquisition of Pseudomonas aeruginosa in
children with cystic fibrosis identified by newborn screening. Pediatr
Pulmonol 2003;35(4):257–62.
[15] Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A,
et al. Comprehensive analysis of risk factors for acquisition of
Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr
Pulmonol 1998;26(2):81–8.
[16] Kubesch P, Dork T, Wulbrand U, Kalin N, Neumann T, Wulf B, et al.
Genetic determinants of airways' colonisation with Pseudomonas
aeruginosa in cystic fibrosis. Lancet 1993;341(8839):189–93.
[17] De Braekeleer M, Allard C, Leblanc JP, Aubin G, Simard F. Genetic
determinants of Pseudomonas aeruginosa colonization in cystic fibrosis
patients in Canada. Eur J Clin Microbiol Infect Dis 1998;17(4):269–71.
[18] Goubau C, Wilschanski M, Skalicka V, Lebecque P, Southern KW,
Sermet I, et al. Phenotypic characterisation of patients with intermediate
sweat chloride values: towards validation of the European diagnostic
algorithm for cystic fibrosis. Thorax 2009;64(8):683–91.
[19] Green DM, McDougal KE, Blackman SM, Sosnay PR, Henderson LB,
Naughton KM, et al. Mutations that permit residual CFTR function delay
acquisition of multiple respiratory pathogens in CF patients. Respir Res
2010;11:140.
[20] Wang SS, FitzSimmons SC, O'Leary LA, Rock MJ, Gwinn ML, Khoury
MJ. Early diagnosis of cystic fibrosis in the newborn period and risk of
Pseudomonas aeruginosa acquisition in the first 10 years of life: a
registry-based longitudinal study. Pediatrics 2001;107(2):274–9.
[21] Sims EJ, McCormick J, Mehta G, Mehta A. Neonatal screening for cystic
fibrosis is beneficial even in the context of modern treatment. J Pediatr
2005;147(3 Suppl.):S42–6.
453M. Rosenfeld et al. / Journal of Cystic Fibrosis 11 (2012) 446–453[22] Baussano I, Tardivo I, Bellezza-Fontana R, Forneris MP, Lezo A, Anfossi
L, et al. Neonatal screening for cystic fibrosis does not affect time to first
infection with Pseudomonas aeruginosa. Pediatrics 2006;118(3):888–95.
[23] Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G,
Gibson RL, Williams J, et al. Early anti-pseudomonal acquisition in young
patients with cystic fibrosis: rationale and design of the EPIC clinical trial
and observational study'. Contemp Clin Trials 2009;30(3):256–68.
[24] Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G,
Graff GR, et al. Baseline characteristics and factors associated with
nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC
observational cohort. Pediatr Pulmonol 2010;45(9):934–44.
[25] Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting
GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through
older adults: Cystic Fibrosis Foundation consensus report. J Pediatr
2008;153(2):S4–S14.
[26] McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype
on phenotype and mortality in cystic fibrosis: a retrospective cohort study.
Lancet 2003;361(9370):1671–6.
[27] Rowntree RK, Harris A. The phenotypic consequences of CFTR
mutations. Ann Hum Genet 2003;67(Pt. 5):471–85.
[28] Collaco JM, McGready J, Green DM, Naughton KM, Watson CP, Shields
T, et al. Effect of temperature on cystic fibrosis lung disease and
infections: a replicated cohort study. PLoS One 2011;6(11):e27784.
[29] Matsui H, Wagner VE, Hill DB, Schwab UE, Rogers TD, Button B, et al.
A physical linkage between cystic fibrosis airway surface dehydration and
Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A
2006;103(48):18131–6.
[30] Bajmoczi M, Gadjeva M, Alper SL, Pier GB, Golan DE. Cystic fibrosis
transmembrane conductance regulator and caveolin-1 regulate epithelial
cell internalization of Pseudomonas aeruginosa. Am J Physiol Cell
Physiol 2009;297(2):C263–77.
[31] Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP,
Davis GJ, et al. Cystic fibrosis pigs develop lung disease and exhibit
defective bacterial eradication at birth. Sci Transl Med 2010;2(29):29ra31.[32] Levy H, Kalish LA, Cannon CL, Garcia KC, Gerard C, Goldmann D, et al.
Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.
Pediatr Pulmonol 2008;43(5):463–71.
[33] Ranganathan SC, Parsons F, Gangell C, Brennan S, Stick SM, Sly PD.
Evolution of pulmonary inflammation and nutritional status in infants and
young children with cystic fibrosis. Thorax 2011;66(5):408–13.
[34] Ortiz JR, Neuzil KM, Victor JC, Wald A, Aitken ML, Goss CH.
Influenza-associated cystic fibrosis pulmonary exacerbations. Chest
2010;137(4):852–60.
[35] Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood
K, et al. Diagnostic accuracy of oropharyngeal cultures in infants and
young children with cystic fibrosis. Pediatr Pulmonol 1999;28(5):321–8.
[36] Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M,
Kronmal R, et al. Comparative efficacy and safety of 4 randomized
regimens to treat early Pseudomonas aeruginosa infection in children with
cystic fibrosis. Arch Pediatr Adolesc Med 2011;165(9):847–56.
[37] Griffiths AL, Jamsen K, Carlin JB, Grimwood K, Carzino R, Robinson PJ,
et al. Effects of segregation on an epidemic Pseudomonas aeruginosa
strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 2005;171(9):
1020–5.
[38] Hayes Jr D, West SE, Rock MJ, Li Z, Splaingard ML, Farrell PM.
Pseudomonas aeruginosa in children with cystic fibrosis diagnosed
through newborn screening: assessment of clinic exposures and microbial
genotypes. Pediatr Pulmonol 2010;45(7):708–16.
[39] Collaco JM, Vanscoy L, Bremer L, McDougal K, Blackman SM, Bowers
A, et al. Interactions between secondhand smoke and genes that affect
cystic fibrosis lung disease. JAMA 2008;299(4):417–24.
[40] Saiman L, Siegel J. Infection control recommendations for patients with
cystic fibrosis: microbiology, important pathogens, and infection control
practices to prevent patient-to-patient transmission. Am J Infect Control
2003;31(3 Suppl.):S1–S62.
